The next phase of Covid - 19 vaccine campaign is becoming more common

7 minutes
The next phase of Covid - 19 vaccine campaign is becoming more common

The Covid 19 development of vaccines is one of medicine’s greatest achievements but distribution hasn't been easy.Vials full of doses sometimes have to be opened in extreme cold and temporarily force health workers to run out into the street in order to find someone to take the leftovers.

Now that the vaccination campaigns in the US and some other countries are moving from mass demand to more targeted efforts to reach the hesitant - and doctors want easier ways to deliver shots.

The ideal in many instances would be a prefilled syringe, simple to store with no excess to worry about.But drugmakers haven't made this a priority yet, and other measures being taken to deliver vaccines to smaller, farther-flung populations are coming along slowly, presenting a challenge in the next phase of the immunization effort.

Doctors' offices and clinics have the desire to reach people in their persuadable moments, Kentucky Public Health Commissioner Steven Stack said April 21 at a briefing hosted by the Association of State and Territorial Health Officials."But it's difficult to do that when these products are shipped in five dose vials or even sometimes 10-dose vials.

Large shipping of vials vaccinated to the brim suit the needs of a campaign aimed at eventually vaccinating most of world's population.According to Bloomberg's vaccination tracker, more than one billion shots have been administered globally and more than a fifth of these worldwide alone in the United States.Large lots remain a priority globally, even as the US campaign enters a new, more targeted stage of course.

Long the container of choice for immunizations, single-dose vials consist of only a glass vessel and rubber stopper.Although they require less testing and are cheaper to use than syringes pre-filled, the vaccine within them expires six to 12 hours after their first use.

Almost one third of Americans are fully immunized, but getting to a level at which the vaccines will keep the virus at bay will increasingly require reaching residents who have misgivings about the shots.Those are most likely to be given at places like primary clinics and clinics where fewer doses could be needed each day, experts said.

'In the rapid effort to make vaccines available as quickly as possible, the best and fastest option was to go to multi-dose vials, says Bernie Clark, vice president of biologics marketing and strategy for Catalent Pharma Solutions. There will be different needs in the future compared to when we were in the middle of the pandemic last year.

Pre-filled syringes could become more common in the next year or two, said Christopher Cassidy, Vice President of Chemical Systems at Schott North America, a maker of both vials and syringes.The need will be particularly great when boosters are triggered to combat new variants of coronavirus, he said.

Yet these devices aren't the major focus for vaccine manufacturers that have been racing to get developed, cleared and distributed shots.Pfizer Inc., whose Covid vaccine developed with partner BioNTech SE was the first authorized in the USA, isn’t currently developing a pre-filled version, a spokesman said.According to a spokesperson, Moderna Inc. hasn't been the first priority to come up with a slightly more convenient package either.

Schott and Catalent, which also makes prefilled syringes, say they are in talks with companies around Covid vaccines, but that the shift will take time.Becton Dickinson and Co., one of the top manufacturers of syringes, has said it will invest about $1.2 billion over four years on biotechnology to manufacture other syringes and other drug delivery systems that could also be of use for pandemic response.

Last year the US government granted a privately held service called ApiJect Systems Corp. a $138 million contract to produce pre-filled syringes for Covid shots.At the time, ApiJect, which doesn't have a history of making the devices, said that it would reach 100 million by the end of the year and half a billion by the end of 2021.A $590 million government loan to cover the work was finalized and funded by Stamford based Company, which hasn’t been approved or approved.

NBC reported last week that ApiJect has not produced any pre-filled syringes for commercial use.The company has manufactured some devices, currently being tested by the drugmakers, that require regulatory review before they are sold, according to Steven Hofman, a spokesman.

He said ApiJect can produce 45 million doses a month through a partnership with a contract building manufacturer in South Carolina, which is expected to be delivered in May.The plan to make 100 million syringes in 2020 is dependent on the availability of vaccine and regulatory approval, he said.

When we got the contracts there was a degree of uncertainty as to whether there would be enough glass throughls and syringes for the vaccine rollout, concerns that have since eased, Hofman said.

Other modifications - making shots that can be more easily filled at warmer temperatures, and generating booster shots - should be higher priority than prefilled syringes, said Nicole Lurie, a strategic adviser to the Coalition for Epidemic Preparedness Innovations, which funds Covid vaccine development.When she worked as a health and human services official during the pandemic of H1 N 1 swine flu, Lurie said, produced prefilled syringes came at the expense of time and volume.

'None will ever be completely happy with everything, she said on Thursday.So prioritizing is really, really important.

Other steps are being taken to make dosing easier.Pfizer, which ships its vaccines in packages of 1,170 doses, will also begin at the end of May with smaller 25 vial pack sizes that contain 450 doses.The move will give flexibility to the U.S. vaccine supply sites, said Tanya Alcorn, Vice President of Biopharma Global Supply Chain.

Pfizer, whose vaccine needs to be stored in an ultra-cold freezer, is also developing new formulations, including a standard six-dose vial that could be ready by the end of the year and would be kept in a cool area.A freeze-heated powder version, which is stored in a vial as a single dose and could be refrigerated, is aimed at early 2022.

The company is also trying to discover whether its currently available vaccine, which can be stored in a refrigerator for only five days, can be kept there for longer periods already.It's one of the most common questions that Pfizer receives from providers of health care, Alcorn said.

We are always thinking about different infrastructures.Different countries have different needs.She said even within a nation you have places, you have rural areas.It is important for us to have different programs and different offerings.

Moderna also said earlier Thursday it was developing a version of its vaccine that could be stored at refrigerator temperatures for three months to facilitate distribution to doctors' offices and other smaller environments.The vaccine is currently stored in a standard refrigerator for one month and up to seven months in a temperature controlled freezer.

Such changes will make it easier for rural clinics and urgent departments, which typically have fridges but may not have deep freezers to store shots, said ZS, a principal at consulting firm ZS who advises manufacturers of Covid vaccines.

Requests for pre-filled syringes are probably good news.It means that we are not far in the vaccine process when moderation of the virus starts to matter, he said.In much of the world, '' is a luxury.

For more articles like this, visit and go to

Subscribe now to stay ahead with the most trusted business news source.

  • Comments
Loading comments...